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Background: Infantile hemangioma (IH) is a benign vascular neoplasm that arises from the abnormal proliferation
of endothelial cells and enhanced angiogenesis. Recently, propranolol has been found to be effective in the
management of IH, suggesting that β-adrenergic receptors (β-ARs) may play an important role in the pathogenesis
of IH.
Results: In the present study, we investigated the β-adrenergic signaling that is associated with
hemangioma-derived endothelial cell (HemEC) proliferation. The results showed that both β1- and β2-ARs were
expressed in HemECs. Stimulation of the β-ARs by isoprenaline induced cell proliferation and elevation of second
messenger cAMP levels. The proliferation-promoting action of isoprenaline was abolished by a β1-selective
antagonist and was more effectively abolished by a β2-selective antagonist; the mechanism for the action of the
antagonists was a G0/G1 phase cell cycle arrest which was associated with decreased cyclin D1, CDK-4, CDK-6 and
phospho-Rb expression. Pre-treatment of the cells with VEGFR-2 or ERK inhibitors also prevented the
isoprenaline-mediated proliferation of cells. In agreement with the involvement of β-ARs and VEGFR-2 in the
HemEC response, β-AR antagonists and the VEGFR-2 inhibitor significantly attenuated isoprenaline-induced ERK
phosphorylation. Moreover, treating the cells with isoprenaline markedly increased VEGF-A expression and VEGFR-2
activity in a β2-AR-dependent manner.
Conclusions: We have demonstrated that the activation of the β-ARs in the ERK pathway may be important
mechanisms in promoting HemEC growth. Furthermore, stimulation of the β-AR may transactivate VEGFR-2
signaling and further increase HemEC proliferation.
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Infantile hemangioma (IH) is the most common form of
vascular tumor, affecting 5% to 10% of all infants and up to
30% of premature infants [1,2]. IHs occur more frequently
in females than in males (at a ratio of 3:1) [3] and generally
appear within the first weeks postpartum, proliferate
rapidly during the first years of life, and spontaneously
involute over a subsequent period of several years. The
proliferating and involuting phases of IHs represent a
gradual shift in the balance of the mitotic and apoptotic* Correspondence: likai2727@163.com
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reproduction in any medium, provided the oractivities of the local endothelial cell population [4]. It has
been demonstrated that vascular endothelial growth factor
(VEGF) is involved in the proliferating phase of IH [5-7].
VEGF is the most potent stimulator of hemangioma-
derived endothelial cell (HemEC) proliferation and diffe-
rentiation [8], and the factor exhibits its pro-proliferative
and pro-angiogenic functions by binding to the tyrosine
kinase receptor VEGFR-2 on HemECs [9]. Many reports
have confirmed that excessive VEGF expression in IH tissue
parallels the proliferating phase of IH tissue growth.
Conversely, during the involuting phase, VEGF expression
rapidly decreases, and many inhibitors of angiogenesis are
instead expressed [5-7].
For most children with IH, the lesions are small and
pose no threat or potential for complication, but in somehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function, or even threaten life. Standard treatment
options for IH include corticosteroids or surgical exci-
sion or, in life- or sight-threatening cases, treatment with
vincristine, interferon or cyclophosphamide. Unfortu-
nately, none of these therapeutic modalities is ideal due
to restrictions or potential serious side effects [10-12]. In
2008, Léauté-Labrèze et al. [13] showed that propranolol
has an anti-proliferative effect on severe IHs. After
this report, a number of studies further demonstrated
that β-blockers other than propranolol were effective
at halting hemangioma growth with few adverse side
effects [14-21]. β-blockers are now the preferred
treatment for problematic proliferating IHs.
To date, it is unknown how β-blockers exert its
pharmacologic effect on IHs. The β-ARs, a family of
G-protein-coupled receptors that are activated by
adrenergic catecholamines, can initiate a series of
signaling cascades, thereby leading to multiple cell-
specific responses. There is evidence suggesting that
endogenous catecholamines play a role in basic develop-
mental processes (e.g., embryogenesis and morphogenesis)
including the control of cell proliferation, differentiation
and migration [22-24]. Recent studies have demonstrated
that in endothelial and various cancer cells, a number of
β-AR agonists, including epinephrine, norepinephrine and
isoprenaline, can induce the proliferation and activation of
mitogen-activated protein kinase (MAPK) family mem-
bers by extracellular signal-related kinase (ERK) [25-28].
ERK and MAPK are serine/threonine kinases that
phosphorylate nuclear transcription factors and regulate
the expression of multiple genes involved in cell prolifera-
tion. VEGF-A participates in this process because a
VEGF-A-specific antibody blocks β-AR-mediated cell pro-
liferation and ERK activation [9,25]. Additionally, VEGF-A
exerts its pro-proliferative and pro-angiogenic effects, at
least partially, by activating the ERK cascade [25,29]. In
primary endothelial cells, VEGFR-2 also associates with
activated ERK in a Ras-independent manner [30].
The mechanisms of β-AR-stimulated tumor growth
have been studied for several years, but the potential role
of the β-ARs in IH pathogenesis has not been investi-
gated. Accordingly, this study examined the mechanisms
underlying the relationship between the β-adrenergic
signaling pathway and the proliferation of HemECs.
Methods
Reagents and antibodies
Endothelial basal medium (EBM-2) and SingleQuot,
which contains human epidermal growth factor, vascular
endothelial growth factor, human basic fibroblast growth
factor, insulin-like growth factor, hydrocortisone, heparin,
ascorbic acid, and gentamicin/amphotericin B, were
obtained from Lonza (Walkersville, MD). Fetal bovineserum (FBS) and phosphate-buffered saline (PBS)
were purchased from Gibco (Grand Island, NY). The
anti-CD31 FITC antibody used in fluorescence-activated
cell sorting (FACS) was obtained from BD Pharmingen
(San Jose, CA). ICI 118551 (ICI), metoprolol (MET),
isoprenaline (ISO), forskolin, collagenase A, bovine
serum albumin (BSA), Hoechst 33342, propidium iodide,
DNase-free RNase, the ERK/MAPK inhibitor, U0126, the
phosphodiesterase inhibitor, 3-isobutyl-methylxanthine
(IBMX), and the cAMP antagonist, Rp-cAMP, were
purchased from Sigma (St. Louis, MO). The VEGFR-2
inhibitor, PTK787, was obtained from Novartis Pharmaceu-
ticals (Basel, Switzerland). The BrdU cell proliferation assay
kit was obtained from Calbiochem (Darmstadt, Germany),
and the cAMP assay kit was obtained from Amersham
Pharmacia Biotech (Braunschweig, Germany). The primary
polyclonal antibodies recognizing the VEGF-A, β1-AR,
β2-AR, phospho-ERK (Thr202/Tyr204) and ERK were
purchased from Santa Cruz Biotechnology (Delaware, CA).
The antibodies for cyclin D1, CDK-4, CDK-6, retinob-
lastoma (Rb), phospho-Rb, phospho-VEGFR-2 (Tyr1175)
and VEGFR-2 were purchased from Cell Signaling Tech-
nology (Boston, MA). Human umbilical vein endothelial
cells (HUVECs) were obtained from Chinese Academy of
Sciences (Shanghai, China).
Preparation of hemangioma specimens
This study was approved by the Ethics Committee of the
Children’s Hospital of Fudan University. Proliferating
infantile hemangioma was surgically removed from a
4-month-old female patient who was referred to our
department for a rapidly growing mass. Written
informed consent was obtained from parents for all
tissue obtained for the study. The clinical diagnosis of vas-
cular neoplasm was confirmed by the Department of
Pathology at the Children’s Hospital of Fudan University
based on staining for GLUT-1, a marker specific for
hemangioma tissue. The tissues were used immediately in
cell isolation and in vitro experiments.
Cell extraction, isolation and culture
HemEC isolation was performed as described previously
[7,8]. Briefly, the hemangioma samples were rinsed in
PBS, minced, and digested with 0.2% collagenase A at
37°C for 1 h. The tissue was homogenized and filtered
through 100 μm cell strainers to dissociate aggregates,
and red blood cells were lysed by incubating the samples
in NH4Cl. Next, the samples were filtered through a
40 μm cell strainer to obtain a single-cell suspension.
CD31+ HemECs were isolated by FACS using anti-CD31
FITC antibodies and were plated on gelatin-coated
60 mm plates in EBM-2 medium supplemented with
20% heat-inactivated FBS, SingleQuot, penicillin (100
units/ml) and streptomycin (100 μg/ml). The cells were
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Cells at passage 3 to 6 were used for experiments.
The purity of the HemECs was >95% as determined
by positive von Willebrand factor and CD31 expression,
and by negative expression of vimentin (fibroblasts) and
α-actin (vascular smooth muscle cells) as previously
described [8].
Analysis of β-ARs expression
The mRNA of the β1- and β2-ARs expressed in HemECs
was isolated using Trizol reagent (Invitrogen, Carlsbad,
CA) and reverse transcribed into cDNA. Quantitation of
the relative mRNA abundance was performed using an
ABI Prism 7700 Sequence Detection System (Applied
Biosystems). The glyceraldehyde-3 phosphate dehydro-
genase (GAPDH) gene served as an internal control.
The abundance of transcripts in the cDNA sample was
measured by real-time PCR using specific primers
according to the manufacturer’s instructions. The pri-
mers are listed in Table 1. The samples were performed
in triplicate. For each experimental condition, at least
three replicates were performed. Differences in threshold
cycles between the target genes and the housekeeping
gene (GAPDH) were calculated.
Western blot analysis of β-AR protein expression in
HemECs was performed as previously described [26].
Briefly, protein was extracted from cultured cells in
radioimmunoprecipitation assay lysis buffer for 20 min
on ice. The proteins were electrophoretically separated
in 10% polyacrylamide gels, transferred to Hybond-ECL
membranes (Amersham Bioscience), probed with either
the β1-AR or β2-AR primary antibody overnight at 4°C
and then probed again with secondary antibodies for
30 min. The protein bands were visualized using
enhanced ECL-associated fluorography.
Cell treatment
Before each treatment, the cells were plated and cultured
in standard media as described above. After 24 h of
incubation to allow for cell attachment, the cells were
washed twice with PBS and synchronized by serum star-
vation for 24 h in EBM-2 medium containing 0.1% BSA.
The medium was then removed and replaced with fresh
medium containing 5% FBS. Different concentrations ofTable 1 Primers used for RT-PCR analysis
Gene Primer
β1-Adrenoceptor forward 50- CTC
(NM000684) reverse 50- AGG
β2-Adrenoceptor forward 50- ACG
(NM000024) reverse 50- CAC
GAPDH forward 50-CTCA
(NM001256799) reverse 50–ATGISO were added to the cells for various times to study
its mitogenic effect. To examine the effects of various
antagonists or inhibitors, the cells were pre-treated with
the antagonists or inhibitors for 1 h before ISO treatment.
SingleQuot was excluded during cell treatment.
BrdU cell proliferation assay
A BrdU cell proliferation assay was performed according
to the manufacturer’s instructions. Briefly, fresh culture
medium containing BrdU (1:2000) was added, and the
cells were incubated for 18 h at 37°C. After washing,
200 μl of fixative/denaturing solution was added to each
well, and the cells were incubated for 30 min at room
temperature. The cells were then treated with an anti-
BrdU antibody (1:100) for 1 h at room temperature. For
conjugation of the peroxidase goat anti-mouse IgG to
the anti-BrdU antibody, 100 μl of the conjugate solution
containing the secondary antibody was added to each
well. Free conjugates were removed by washing with
wash buffer three times and with distilled water once.
After removal of the contents of the well, the reaction
was stopped by adding stop solution, and the absor-
bances of the wells were read at 520 nm on an automatic
microplate reader (Bio-Rad, CA).
Quantification of viable cells
HemECs were plated in a 96-well plate and incubated in
the absence or presence of various chemicals. The number
of viable cells was determined using a CCK-8 assay kit.
Briefly, 10 μl of the CCK-8 solution was added to each
well, and the plate was incubated for 2 h. The absorbance
of each well was measured at 450 nm using a microplate
reader (Bio-Rad, CA).
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry
(Beckman Coulter, Brea, CA). After treatment, the cells
were trypsinized, centrifuged at 1,000 × g for 5 min,
collected and washed with ice-cold PBS. Next, the cell
pellets were resuspended and fixed with cold 70%
ethanol overnight. After another wash with PBS, the cell
pellets were resuspended in 1 ml of staining solution
containing propidium iodide (PI, 50 μg/ml), DNase-free
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incubated at 37°C for 30 min in the dark before analysis.
The fraction of the cell population in each phase of the
cell cycle was determined as a function of the DNA
content using flow cytometry analysis.
cAMP assay
The intracellular cAMP assay was performed according
to the manufacturer’s recommendations. In brief, 1 × 106
cells were treated without or with ISO (1 μM) for 5 min in
the presence of 100 μM IBMX. The cells were then
scraped and lysed with lysis buffer (Amersham Pharmacia
Biotech, Braunschweig, Germany). The levels of cAMP
were measured using the enzyme immunoassay method
and were expressed as picomoles of cAMP per milligram
of protein.
Western blot analysis
Western blot analysis using antibodies against cyclin D1,
CDK-4, CDK-6, phospho-Rb, Rb, VEGF-A, phospho-
VEGFR-2 (Tyr1175), VEGFR-2, phospho-ERK and ERK
was performed on extracted proteins as previously
described [9,31]. The proteins were visualized by ECL,
and the intensity of the signal was quantified by
scanning laser densitometry.
Statistical analysis
All data were expressed as the mean ± SD with n = 3 for
each sample for all of the paired statistical comparisons.
The analysis of variance (ANOVA) test followed by
Tukey’s t-test was performed, and a P value less than
0.05 was considered statistically significant.Figure 1 Expression of β-ARs in HemECs. A, Real-time PCR expression a
represented as the relative abundance of each target gene normalized to t
in HemECs. Cell lysates probed for β1-AR revealed two bands with an appa
bands were observed when HemEC lysates were probed for β2-AR: one ba
bands were not observed in blots incubated with normal rabbit serum (noResults
Expression of β-ARs in HemECs
Expression of the β1- and β2-ARs in HemECs was
measured at the mRNA and protein levels by quantita-
tive real-time PCR and Western blotting, respectively.
HUVEC were used as control. The real-time-PCR results
showed that the HemECs constitutively expressed the
transcripts for both the β1- and β2-ARs (Figure 1A).
Western blot analysis of β1- and β2-AR expression in the
lysates of HemECs showed that these cells also
expressed both of the β-ARs (Figure 1B).
ISO increased HemECs proliferation, and the effect was
reversed by β-AR antagonists
The effect of ISO on BrdU incorporation by HemECs
was examined by using various concentrations of ISO
(0-10 μM) for 12 h or by treating HemECs with a fixed
concentration of ISO (1 μM) for various times (0-36 h).
As shown in Figure 2A and B, the level of BrdU incorp-
oration increased at a 10 nM concentration of ISO, with
a maximum stimulatory effect observed at 1 μM.
Increased BrdU incorporation was first observed at 6 h;
this effect peaked at 12 h and gradually decreased over a
24 h period. In addition, a significant increase in the
number of cells was observed after incubation of the
cells with 1 μM ISO for 12 h (Figure 2D).
The β1-selective antagonist, MET (10 μM; β1:β2 recep-
tor activity, 10:1), and the β2-selective antagonist, ICI
(10 μM; β1:β2 receptor activity, 1:100), were used to
determine whether β1- and β2-ARs mediated the stimu-
latory action of ISO. The results showed that neither
antagonist had an effect on basal cell proliferation, butssays measure the β1- and β2-AR expression in HemECs. The data are
he GAPDH levels. B, Western blot analysis of β1- and β2-AR expression
rent molecular weight of 65-75 kDa, and one band at 51 kDa. Two
nd with molecular weights of 47 kDa, another band at 90 kDa. These
t shown).
Figure 2 Role of β-ARs in the proliferation of HemECs. A, Incubation of HemECs with ISO for 12 h increased DNA synthesis in a dose-
dependent manner with an EC50 of 340 ± 41 nM. HemECs were incubated in EBM-2 with 5% FBS and synchronized for 24 h in EBM-2 with 0.1%
BSA prior to stimulation. B, HemECs were incubated in the presence of 1 μM ISO for various times (0-36 h). C, The effects of β1- and β2-AR
blockade with MET and ICI on ISO-induced HemECs proliferation. HemECs were pre-treated with MET or ICI for 1 h followed by the addition of
1 μM ISO. ICI more efficiently blocked ISO-enhanced cell proliferation. D, The number of viable cells was counted using CCK-8. ISO treatment
increased cell number, whereas MET and ICI prevented the ISO-induced increase in cell number. The results are shown as the mean ± SD of
triplicate assay from one of three identical experiments. * P<0.05 when compared with the ISO-untreated control, † P<0.05 when compared with
the ISO-treated control, # P<0.05 when compared with the MET-treated group.
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tion and cell viability. ICI was more effective than MET
in reducing the ability of ISO to promote both cell pro-
liferation and a change in cell number as showed by
BrdU and CCK-8 assays, respectively (Figure 2C and D).
The expression cell cycle regulators was upregulated by
ISO but inhibited by β-AR antagonists
To investigate the mechanism responsible for β-AR
stimulation of cell proliferation, we performed a cell
cycle analysis in HemECs. As shown in Figure 3A and B,
ISO promoted cell cycle progression from the G1 to S
phase. Pre-treatment of HemECs with MET or ICI
resulted in a greater number of cells in the G0/G1 phase
and a lesser number of cells in the S phase when
compared with HemECs treated with ISO alone.
Cell cycle progression is controlled by cyclins, CDKs,
Rb and many other proteins. When stimulated with
mitogens, dormant cells enter the cell cycle by activating
cyclin D1 and its cyclin-dependent kinases, CDK-4 and
CDK-6, and by phosphorylating the Rb protein to release
E2F transcription factors [32]. To determine the level of
expression of these cell cycle regulators in HemECs after
ISO treatment, immunoblotting was performed. Western
blot analysis confirmed that ISO not only increased theexpression of cyclin D1 and its associated kinases, CDK-4
and CDK-6, but also induced the phosphorylation of Rb
when compared with the control group. In contrast, pre-
treatment of HemECs with β-AR antagonists significantly
inhibited the stimulating effect of ISO on these regulators
(Figure 3C, D).
Cyclic AMP levels in HemECs were elevated upon ISO
treatment
In the classic model of β-adrenergic signaling, receptor
activation results in the dissociation of the heterotri-
meric G-protein, and the Gαs subunit stimulates adenylyl
cyclase to produce cAMP and activate the downstream
protein kinase A (PKA)-mediated signaling pathway [33].
To determine whether activation of the β-ARs in HemECs
resulted in the production of cAMP, intracellular levels of
cAMP were measured in the presence or absence of ISO.
Treatment with 1 μM ISO for 5 min produced a signifi-
cant increase in cAMP production in HemECs; cAMP
levels were increased by nearly 3.4-fold relative to the
control. However, the increased cAMP levels induced by
ISO were significantly reduced by pre-treatment with the
β-AR antagonists (Figure 4). In addition, pre-treatment of
cells with the cAMP antagonist, Rp-cAMP, prevented the
ISO-induced proliferation of cell (Figure 5).
Figure 3 Expression of cell cycle regulators was upregulated by ISO but abolished by β-AR antagonists. A, Cell cycle analysis was
performed to determine the different phases of the cell cycle that occurred when HemECs were treated with or without ISO, MET or ICI. The data
shown were collected from 10,000 events. B, Histogram distribution of cells in the G0/G1, S and G2/M phases as determined by flow cytometry. C,
Western blot analysis of cyclin and CDK protein expression. The expression of cyclin D1, CDK-4 and CDK-6 was upregulated by ISO but abolished
by MET or ICI. GAPDH served as the loading control. D, Western blot analysis of Rb phosphorylation. ISO caused the phosphorylation of Rb, and
this effect was inhibited by MET or ICI. Total Rb (tRb) was used for normalization. Data are representative of three independent experiments.
* P<0.05 when compared with the ISO-untreated control, † P<0.05 when compared with the ISO-treated control.
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ISO on cell proliferation
VEGFR-2 is the most biologically important receptor for
VEGF-A in tumors. It regulates endothelial cell migra-
tion, proliferation and survival. Following the binding of
VEGF-A, VEGFR-2 dimerizes and autophosphorylates
the tyrosine residues in its cytoplasmic domain [34,35].
Tyr1175 is one of the major autophosphorylation sites in
VEGFR-2, and phosphorylation of Tyr1175 mediates theactivation of the MAP kinase ERK, which is essential in
regulating endothelial cell proliferation [36].
To verify whether VEGFR-2 and ERK were involved
in ISO-induced cell proliferation, HemECs were pre-
treated with pharmacological inhibitors of VEGFR-2
(PTK787) and ERK (U0126) and were stimulated with
1 μM ISO. The results showed that pre-treatment
with PTK787 significantly inhibited the ISO-induced
cell proliferation of HemECs, and U0126 caused a
Figure 4 Intracellular cAMP production was enhanced by ISO but reversed by β-AR antagonists. A, cAMP levels after 5 min stimulation
with the indicated concentrations of ISO. Curve was drawn according to simple Michaelis-Menten kinetics, yielding an EC50 of 180 ± 37 nM. B,
HemECs were pre-treated with 10 μM MET or 10 μM ICI for 1 h followed by stimulation with 1 μM ISO for 5 min. Positive controls consisted of
cells treated with only 100 μM forskolon for 5 min. All reactions took place in the presence of 100 μM IBMX. cAMP levels were measured using
the enzyme immunoassay method. The results are shown as the mean ± SD of triplicate assays from one of three identical experiments. * P<0.05
when compared with the ISO-untreated control, † P<0.05 when compared with the ISO-treated control.
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(Figure 5).
The ISO-induced phosphorylation of ERK was abolished
by β-AR antagonists and PTK787
Because the ISO-induced proliferation of HemECs was
reduced by pre-treatment with an ERK inhibitor, ERK
may be involved in the signal transduction pathway that
is activated by ISO. To investigate this hypothesis,
changes in the phosphorylation status of ERK were
determined. Equal amounts of cell lysates were used to
detect activated ERK using anti-phospho-ERK antibodies.
The results showed that treating cells with ISO signifi-
cantly increased ERK phosphorylation, which reached
a maximum 30 min after ISO treatment (Figure 6A).Figure 5 Role of cAMP production and VEGFR-2 and ERK
activation on ISO-induced cell proliferation. HemECs were pre-
treated with the cAMP antagonist, Rp-cAMP (10 μM), the VEGFR-2
inhibitor, PTK787 (10 μM), or the MAPK kinase inhibitor, U0126
(1 μM), for 1 h, incubated with 1 μM ISO for 12 h, and pulsed with
1:2,000 BrdU for 18 h. The results are shown as the mean ± SD of
triplicate assays from one of three identical experiments. * P<0.05
when compared with the ISO-untreated control, † P<0.05 when
compared with the ISO-treated control.Pre-treating the HemECs with MET or ICI signifi-
cantly decreased ERK phosphorylation, indicating that
the ISO-induced cell proliferation of HemECs was
dependent on the activity of ERK. Next, we assessed
whether ISO-mediated ERK activation was dependent
on VEGFR-2 activity. In the presence of PTK787,
ISO-mediated ERK activation was inhibited (Figure 6B).
ISO increased VEGF-A expression and VEGFR-2 activation,
both of which were inhibited by ICI
We next examined whether ISO had an effect on VEGF-A
expression and phosphorylation of VEGFR-2 at Tyr1175.
The results showed that treating HemECs with ISO
significantly increased VEGF-A expression. In con-
trast, pre-treatment of cells with ICI or U0126 signifi-
cantly suppressed VEGF-A expression (Figure 7A).
VEGFR-2 phosphorylation peaked 3 h after ISO treat-
ment (Figure 7B). Pre-treating HemECs with ICI or a
VEGF neutralizing antibody significantly abolished
VEGFR-2 phosphorylation. However, MET had no
effect on ISO-induced VEGF-A expression or VEGFR-2
phosphorylation. (Figure 7A, C).
Discussion
β-ARs have been reported to participate in the promo-
tion and progression of different neoplasms, including
various types of adenocarcinomas and squamous-cell
carcinomas. In those studies, cancer cell growth was sti-
mulated either by the non-selective adrenergic agonists or
more effectively by the β-selective agonists [26,31,37-39].
The authors suggested that the tumor cells might secrete
low levels of catecholamines to self-stimulate their growth
via the β-ARs [40,41]. It is known that agonist and
antagonist of β-ARs act antithetic via same intracellular
pathways. Recently, β-AR antagonists (e.g., propranolol)
have been found to provide therapeutic leverage in the
Figure 6 Effect of β-AR stimulation on ERK activation in HemECs. A, HemECs were treated with ISO for various times (0-60 min), and ERK
phosphorylation was detected by Western blotting. ERK phosphorylation peaked 30 min after ISO treatment. B, HemECs were pre-treated with
MET (10 μM), ICI (10 μM) or PTK787 (10 μM) for 1 h and incubated with ISO (1 μM) for 30 min. The phosphorylation status of ERK was then
detected. Total ERK was used as an internal control. The experiments were repeated three times, and similar results were obtained. * P<0.05
when compared with the ISO-untreated control, † P<0.05 when compared with the ISO-treated control.
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IH [13-21].
HemECs exhibit an X-chromosome inactivation pattern
of clonality, and show upregulation of some markers and
downregulation of others. This expression pattern is stably
maintained in cultured HemECs and differs from that of
other endothelial cells [8,47,48]. In the present study, we
demonstrated that the β1- and β2-ARs were expressed in
HemECs. Activation of the β-ARs resulted in an increased
concentration of intracellular cAMP and enhanced cell
proliferation, two processes that could be reversed by
treatment with β1- or β2-AR antagonists. Interestingly,
β-AR stimulation has recently been demonstrated to
be a major factor that contributes to the initiation of
IH by Mayer et al. [49], who found that intrauterine
exposure to β2-sympathomimetic hexoprenaline can
increase the occurrence of IH in preterm infants. In
addition, the β2-AR antagonist but not the β1-AR
antagonist completely abolished ISO-induced cell pro-
liferation, suggesting that the mitogenic effect of ISO
predominately occurred through the β2-AR. This finding
is in agreement with a previous report that showed that
the stimulatory effect of ISO on aorta endothelial cells was
preferentially mediated by the β2-AR [25]. However, it was
reported that the current selective β1-blockers in use are
not entirely β1 specific. In fact, MET partially inhibits
β2-AR as well [50]. It is therefore possible that even
limited β2-adrenergic inhibition by MET might be
sufficient to inhibit cell proliferation.Control of cell cycle progression in tumor cells may be
an effective strategy for treating tumors. The current
findings clearly showed that the β-AR antagonists
arrested ISO-treated cells at the G0/G1 phase of the cell
cycle, suggesting that the β-AR antagonists inhibited cell
proliferation via interactions with cell cycle regulators.
Indeed, cyclin D1, CDK-4, CDK-6 and phospho-Rb have
been reported to control the vascular endothelial cell
proliferation during pathogenic neovascularization [51].
We investigated whether the expression of these estab-
lished cell cycle regulators was controlled by the β-ARs
in HemECs. Our results showed that treatment of
HemECs with ISO resulted in a moderate to strong in-
crease in the protein levels of cyclin D1, CDK-4, CDK-6
and phospho-Rb, but these high levels of expression
were reversed by pre-treatment with either the β1- or
β2-AR antagonist. The mechanism responsible for
these changes remains unknown and merits further
investigation.
ERK proteins are reversibly phosphorylated by a variety
of protein kinases and upstream signaling molecules as a
result of the activation of receptor tyrosine kinases and
G-protein-coupled receptors. The β-ARs promoted
vascular endothelial cell ERK activation by at least two
mechanisms. First, stimulation of endothelial β-ARs directly
activated ERK signaling cascades, and second, β-AR stimu-
lation induced the release of VEGF-A, which can also
activate ERK [25]. In the present study, ERK inhibition
prevented HemEC proliferation, demonstrating that this
Figure 7 Effect of β-AR stimulation on VEGF-A expression and VEGFR-2 activation in HemECs. A, HemECs were pre-treated with MET
(10 μM), ICI (10 μM) or U0126 (1 μM) for 1 h and incubated with ISO (1 μM) for 12 h. The expression of VEGF was then measured. GAPDH was
used as an internal control. B, HemECs were treated with ISO for various times (0-20 h), and the phosphorylation level of VEGFR-2 was detected
by Western blot using a phospho-specific antibody against the VEGFR-2 Tyr1175 residue. The ISO-induced phosphorylation of VEGFR-2 at Tyr1175
followed a bell-shaped curve starting at 1 h, reached a peak at 3 h and declined to basal levels after 15 h of treatment. C, HemECs were pre-
treated with MET (10 μM), ICI (10 μM) or 2 μg/ml of a VEGF neutralizing antibody (VEGF Ab) for 1 h before incubating the cells with ISO (1 μM)
for 3 h. The phosphorylation status of VEGFR-2 was then detected. B and C denote the mean ± SD of three experiments for each condition and
was determined by the densitometry values that were determined relative to the total amounts of VEGFR-2. * P<0.05 when compared with the
ISO-untreated control, † P<0.05 when compared with the ISO-treated control.
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proliferation. Moreover, ISO significantly induced ERK
activation, and this effect was abolished by either the β1 or
β2-AR antagonist.
Exposure to a chronic stressor promoted in vivo
angiogenesis and production of VEGF. This effect was
eliminated by silencing tumor cell β-AR expression, im-
plicating tumor cell β-AR expression and signaling as an
important facilitator of stress-induced tumor angiogen-
esis in vivo [39]. In vitro studies using tumor cell lines
suggest that catecholamines can promote tumor pro-
gression by a β-AR-driven proangiogenic pathway. This
stimulation of VEGF expression by β-adrenergic signaling
is proportional to β-AR expression, dose-dependent and
inhibited by β-AR antagonists [37,52]. There is evidencethat expression of VEGF in endothelial cells may also be
controlled by adrenergic stimulation; as demonstrated in
different in vitro and in vivo models, β-AR agonists,
including epinephrine, norepinephrine and ISO, can
induce the expression of VEGF [53-55]. Conversely, β-AR
antagonists (e.g., propranolol) lead to a reduced expres-
sion of VEGF and inhibit cell proliferation and angio-
genesis [29,56]. In the present study, ISO increased the
expression level of VEGF-A in HemECs in a β-AR- and
ERK-dependent manner. These findings are consistent
with previous studies in which β-AR stimulation resulted
in the over-expression of VEGF-A through the β-AR and
ERK signaling cascade [25,31,57].
We also found that the ISO-stimulated activation of
ERK and subsequent proliferation of HemECs required
Ji et al. Cell Division 2013, 8:1 Page 10 of 11
http://www.celldiv.com/content/8/1/1VEGFR-2 activity. Studies have shown that cultured
HemECs share a phenotype of constitutively active
VEGFR-2 signaling, which might render the cells more
sensitive to autocrine or paracrine stimulation of VEGF-A
[9]. The VEGFR-2 intracellular signaling pathway in
HemECs was not fully explored, but results from the
in vitro VEGF-A stimulation of different types of endothe-
lial cells indicated that VEGFR-2 signaling is dependent
on the downstream effects of ERK [29,30,34]. Although
activation of VEGFR-2 and β-ARs has been implicated in
the promotion of cell proliferation, the connection
between these two receptor systems is poorly understood.
Here, we provide the first evidence that the VEGFR-2-
mediated phosphorylation of ERK is upregulated upon
β-AR activation to mediate proliferation of HemECs.
These findings, together with the observation that the
ISO-induced phosphorylation of VEGFR-2 could be
inhibited by ICI, demonstrate that the transactivation
of VEGFR-2 may act as an effector pathway to mediate
the mitogenic effects of the β-ARs.
In conclusion, we demonstrated that activation of the
β-ARs resulted in increased HemEC proliferation and
upregulation of the ERK signaling cascade. VEGFR-2-
mediated ERK signaling was also upregulated upon β-AR
activation to mediate proliferation of HemECs. These
findings not only provide a pharmacological basis for the
therapeutic use of β-AR antagonists in the treatment of
IH but also unveil a functional connection between
the β-ARs and VEGFR-2 in HemECs.
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